Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

With Merck Footing the $200M Bill, Moderna Launches mRNA Cancer Vaccine Clinical Trial

  • Post author:Sam
  • Post published:November 15, 2017
  • Post category:BioPharma

Moderna announced that it has dosed its first patient in a Phase I trial of mRNA-4157, a mRNA-based personalized cancer vaccine. Source: BioSpace

Continue ReadingWith Merck Footing the $200M Bill, Moderna Launches mRNA Cancer Vaccine Clinical Trial

Johns Hopkins Gets a $65M Boost to Take Promising Drugs Into Clinic

  • Post author:Sam
  • Post published:November 15, 2017
  • Post category:BioPharma

Deerfield and Johns Hopkins announce Bluefield Innovations, a collaboration designed to catalyze the development of early stage therapeutics. Source: BioSpace

Continue ReadingJohns Hopkins Gets a $65M Boost to Take Promising Drugs Into Clinic

Verily Ranked #1 for Interesting & Meaningful Work and Competitive Salary

  • Post author:Sam
  • Post published:November 15, 2017
  • Post category:BioPharma

The opportunity to work at the leading edge of science and technology while working on solutions to some of the world's most vexing problems is what attracts people to Verily.…

Continue ReadingVerily Ranked #1 for Interesting & Meaningful Work and Competitive Salary

Regeneron Gets OK for Huge Expansion in Greenburgh, New York

  • Post author:Sam
  • Post published:November 15, 2017
  • Post category:BioPharma

When complete, the expansion is expected to double the size of Regeneron's footprint in Greenburgh. Source: BioSpace

Continue ReadingRegeneron Gets OK for Huge Expansion in Greenburgh, New York

Founded by Genzyme Alumni, Cambridge's X4 Pharma Scores $27M

  • Post author:Sam
  • Post published:November 15, 2017
  • Post category:BioPharma

X4 Pharma announced it had closed a $27M Series B financing. Source: BioSpace

Continue ReadingFounded by Genzyme Alumni, Cambridge's X4 Pharma Scores $27M

Philadelphia Biotech Startup Context Therapeutics Names a New CFO, Effective Immediately

  • Post author:Sam
  • Post published:November 15, 2017
  • Post category:BioPharma

The company is strengthening its team as it transitions to a clinical development stage company. Source: BioSpace

Continue ReadingPhiladelphia Biotech Startup Context Therapeutics Names a New CFO, Effective Immediately

All Systems Go: Johnson & Johnson Reaches Out for Second Ionis GI Drug

  • Post author:Sam
  • Post published:November 15, 2017
  • Post category:BioPharma

Ionis Pharma and Janssen have strengthened their alliance with a second deal for gastrointestinal drugs. Source: BioSpace

Continue ReadingAll Systems Go: Johnson & Johnson Reaches Out for Second Ionis GI Drug

Don't Stop Believing: Teva's R&D Head Gives 3 Reasons Why Investors Should Hold On

  • Post author:Sam
  • Post published:November 15, 2017
  • Post category:BioPharma

Teva's stock jumped as investors get more hopeful about the future. Source: BioSpace

Continue ReadingDon't Stop Believing: Teva's R&D Head Gives 3 Reasons Why Investors Should Hold On

Indian Generics Producer Missed Mark on Tests, FDA Says

  • Post author:Sam
  • Post published:November 15, 2017
  • Post category:Drug Industry Daily

A major manufacturer of generic drugs in India failed to follow up as required on laboratory tests that showed its products at two facilities did not meet specifications, in some…

Continue ReadingIndian Generics Producer Missed Mark on Tests, FDA Says

FDA’s Benefit-Risk Framework is Good, but Needs Work, BIO Says

  • Post author:Sam
  • Post published:November 15, 2017
  • Post category:Drug Industry Daily

The FDA could further improve the transparency of its benefit-risk assessments in drug regulatory decisions by disclosing more information in complete response letters, BIO suggested in written comments to the…

Continue ReadingFDA’s Benefit-Risk Framework is Good, but Needs Work, BIO Says
  • Go to the previous page
  • 1
  • …
  • 255
  • 256
  • 257
  • 258
  • 259
  • 260
  • 261
  • …
  • 610
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.